Drug Trial Radar · NCT06140303
SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Feb 22, 2024
Primary completion
Jan 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- PolarityTEIndustry
- Sponsor type
- Industry
- Collaborators
- Professional Education and Research Institute
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of SkinTE for treatment of Wagner grade 1 diabetic foot ulcers.
Conditions
- Diabetic Foot
Interventions
SkinTEBiological
SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
ControlOther
Standard care is defined in this protocol to include the following: * Debridement * Collagen dressing * Local offloading * Foam * Multi-layer compression dressing * Off-loading device such as a controlled ankle motion (CAM) boot
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of index ulcers closedTime frame: 12 weeks
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Titan Clinical Research
Mesa, Arizona
Center for Clinical Research
Castro Valley, California
Limb Preservation Platform, Inc.
Fresno, California
Angel City Research
Los Angeles, California
Clemente Clinical Research Inc.
Los Angeles, California
Center for Clinical Research
San Francisco, California
Clemente Clinical Research Inc.
Santa Ana, California
ILD Research
Vista, California
Las Mercedes Medical Research, Inc.
Hialeah, Florida
Doctors Research Network
Miami, Florida
DMI Research
Pinellas Park, Florida
Barry University Clinical Research
Tamarac, Florida
FASMA - Hagerstown
Hagerstown, Maryland
Viable Research Management
Henderson, Nevada
Northwell Health, Inc.
New Hyde Park, New York
Mount Sinai West Hospital
New York, New York
LEIRT (Lower Extremity Institute for Research and Therapy)
Boardman, Ohio
Cutting Edge Research LLC
Circleville, Ohio
LEIRT (Lower Extremity Institute for Research and Therapy)
East Liverpool, Ohio
Cutting Edge Research LLC
Grove City, Ohio
Perfizien Clinical Research LLC.
Houston, Texas
Baylor Scott & White Health
Plano, Texas
Foot and Ankle Specialists of the Mid-Atlantic
Salem, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.